U.S. markets close in 2 hours 18 minutes
  • S&P 500

    4,276.82
    -28.38 (-0.66%)
     
  • Dow 30

    33,999.69
    -152.32 (-0.45%)
     
  • Nasdaq

    12,943.69
    -158.86 (-1.21%)
     
  • Russell 2000

    1,987.03
    -33.49 (-1.66%)
     
  • Crude Oil

    88.09
    +1.56 (+1.80%)
     
  • Gold

    1,777.10
    -12.60 (-0.70%)
     
  • Silver

    19.75
    -0.34 (-1.69%)
     
  • EUR/USD

    1.0171
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    2.9060
    +0.0820 (+2.90%)
     
  • GBP/USD

    1.2045
    -0.0049 (-0.41%)
     
  • USD/JPY

    135.4570
    +1.2420 (+0.93%)
     
  • BTC-USD

    23,412.29
    -456.54 (-1.91%)
     
  • CMC Crypto 200

    556.52
    -16.29 (-2.84%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

Singular Genomics Systems, Inc. to Report Second Quarter 2022 Financial Results on August 9, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Singular Genomics Systems, Inc.
Singular Genomics Systems, Inc.

SAN DIEGO, July 28, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter 2022 after the market close on Tuesday, August 9, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at investor.singulargenomics.com, in the Presentations & Events section.

About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine.

Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com

Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com